Abstract
In a prospective phase II study, we evaluated the combination of high dose simvastatin and VAD chemotherapy in patients with refractory or relapsed multiple myeloma. Although treatment was feasible with mild side effects, only 1 of 12 patients achieved a partial response. According to our predefined criteria this was insufficient to continue the study.
Publication types
-
Clinical Trial, Phase II
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Oral
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Clinical Trials, Phase I as Topic
-
Dexamethasone / administration & dosage
-
Dexamethasone / adverse effects
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Drug Resistance, Neoplasm / drug effects*
-
Female
-
Humans
-
Infusions, Intravenous
-
Male
-
Middle Aged
-
Multiple Myeloma / complications
-
Multiple Myeloma / drug therapy*
-
Simvastatin / administration & dosage*
-
Simvastatin / adverse effects
-
Vincristine / administration & dosage
-
Vincristine / adverse effects
Substances
-
Vincristine
-
Dexamethasone
-
Doxorubicin
-
Simvastatin